China Resources Pharmaceutical Group Ltd (3320.HK) said on Monday it would make a 4.28 billion yuan ($667 million) general offer for all outstanding shares of Jiangzhong Pharmaceutical Co Ltd (600750.SS) after a deal to...
GSK exploring merger, share swap with potential buyers
A whopping 40% tax burden might hobble the sale of British pharma giant GlaxoSmithKline’s (GSK) Indian consumer products division and to tip toe around the hurdle it has sought potential buyers open to a merger and...
Aurobindo eyes Mallinckrodt Opioids Again
Even as the Donald Trump administration intensifies its crackdown on the opioid crisis in the US, homegrown Aurobindo PharmaNSE -0.50 % has re-engaged with Mallinckrodt to acquire its specialty generics portfolio. But...
Stempeutics partners with Cipla for its stem cell drug
Biotech firm Stempeutics Research today said it has inked an out-licensing deal with drug major CiplaNSE -3.74 % for its stem cell therapy product Stempeucel, indicated for treating critical limb ischemia. “Under...
Orchid Pharma faces liquidation as lenders reject resolution plan
The lenders to Orchid Pharma have rejected the resolution plan of the bankrupt company, a decision that could push the troubled drug-maker toward liquidation. “The resolution professional has conducted three rounds of...
Strides to merge its Australian biz with Canadian drugmaker Apotex
Indian pharmaceutical company Strides Shasun on Wednesday said that it would merge its Australian business with the local operations of Canadian drugmaker Apotex Inc to create the country’s largest generics drugmaker by...
Japan’s Takeda clinches $62 billion Shire deal as pharma M&A rolls on
Takeda Pharmaceutical agreed to buy London-listed Shire for 45.3 billion pounds ($62 billion) on Tuesday, the biggest yet in a wave of deals sweeping the drugs industry. Assuming it wins the backing of shareholders, the...
Hyderabad’s Aurobindo in race to buy Novartis’ generic dermatology business
After Ahmedabad’s Torrent Pharmaceuticals dropped the idea to acquire Sanofi’s European generic business last month, Hyderabad-headquartered Aurobindo Pharma is in the race to buy the dermatology generics...
Aurobindo launches $1.6 billion bid to buy Novartis generics unit
Aurobindo Pharma Ltd has submitted an initial bid to buy Novartis AG’s dermatology generics drug business for about $1.6 billion, two people directly aware of the development said on condition of anonymity. Hyderabad...
To finance Monsanto acquisition, Bayer sells Covestro stake for $2.64 bn
Pharmaceutical group Bayer has sold a further stake in plastics company Covestro for 2.2 billion euros ($2.64 billion), placing a holding of 14.2 per cent via an accelerated book-building process. Covestro was spun off...
Bayer to sell further Covestro stake for 2.2 billion euros
Pharmaceutical group Bayer (BAYGn.DE) is selling a further stake in plastics company Covestro (1COV.DE), placing a holding of around 14.2 percent via an accelerated book building process. Covestro was spun off from...
Shire says willing to recommend Takeda’s $64 billion offer to shareholders
Rare disease drug maker Shire Plc said on Tuesday it was willing to recommend a sweetened $64 billion offer from Japan’s Takeda Pharmaceutical Co to shareholders, in what could be the biggest acquisition of a drug...
